PharmaTimes Medical & Scientific Excellence Awards and Nursing Industry Excellence Awards are open for entry

May 13, 2024
Business Services MSEA, NIEA, PharmaTimes, awards

Both awards are open for entry until 17 May 2024 and the live awards ceremony will take place on 11 …

Sanofi adds €1bn funding for biomanufacturing projects in France

May 13, 2024
Business Services Biomanufacturing, Pharmacy, Sanofi, funding, investment

Sanofi has announced that it has made a new investment of at least €1bn for the creation of new bioproduction …

Moderna shares update on RSV vaccine

May 13, 2024
Medical Communications FDA, Immunology, Moderna, Vaccine

Moderna has announced that the US Food and Drug Administration (FDA) has shared that it will not complete its review …

genes

Shionogi and Maze Therapeutics announce worldwide exclusive licensing agreement for novel Pompe disease candidate

May 10, 2024
Sales and Marketing Pompe disease, Rare Diseases, Shionogi, licensing agreement, maze therapeutics

Japanese pharmaceutical company Shionogi and US-based Maze Therapeutics have finalised an exclusive worldwide license agreement for MZE001, a novel therapeutic …

Vaccine image

Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines

May 10, 2024
Sales and Marketing COVID-19, COVID-19 vaccine, Immunology, Novatex, Sanofi, flu-COVID-19 vaccine, licensing agreement

French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive licensing agreement for a number …

az_vaccine

AstraZeneca withdraws COVID-19 vaccine Vaxzevria

May 9, 2024
Sales and Marketing AstraZeneca, COVID-19, Immunology, thrombosis with thrombocytopenia syndrome

UK-based pharmaceutical company AstraZeneca has announced that is it voluntarily withdrawing its COVID-19 vaccine Vaxzevria due to a drop in …

dementia image

Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study

May 9, 2024
Research and Development Alzheimer's disease, Neurocrine Biosciences, Neurology, Nxera Pharma, Parkinson's disease, clinical trials, dementia, schizophrenia

Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational …

Mirum Pharmaceuticals publishes phase 3 MARCH maralixibat data in The Lancet

May 8, 2024
Research and Development Hepatology, Mirum Pharmaceuticals, PFIC, The Lancet, clinical trials

Biopharma company Mirum Pharmaceuticals has announced data from its phase 3 MARCH-PFIC study which evaluated maralixibat in patients with progressive …

biology-think-networking-physiology-brain-anatomy-2676370

Circular Genomics reveals study results into predicting patient response to SSRI antidepressant treatment

May 8, 2024
Research and Development Circular Genomics, Psychiatry, SSRI, antidepressant treatment, blood assays

US RNA biomarker company Circular Genomics has announced study results highlighting the company’s first blood assay to predict a patient’s …

lungs

Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib

May 7, 2024
Research and Development Chiesi, Chronic Diseases, Gossamer Bio, PAH, PH-ILD, collaboration

US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have entered into an international agreement …

trials

Broken String Biosciences and the Francis Crick Institute collaborate on ALS research

May 7, 2024
Research and Development Broken String Biosciences, Francis Crick Institute, Neurology, amyotrophic lateral sclerosis, genomics

Genomics company Broken String Biosciences and biomedical discovery institute Francis Crick have announced a research collaboration, focusing on amyotrophic lateral …

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024
Research and Development AbbVie, Pharmacy, R&D, facility

AbbVie has announced that it is investing approximately €150m in its second largest research and development (R&D) facility worldwide. The …

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024
Medical Communications AstraZeneca, Calquence, Oncology, clinical trial, lymphoma

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 trial, which assessed Calquence (acalabrutinib) …

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024
Research and Development Gastric, MSD, Merck, Oncology, keytruda

Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024
Medical Communications COPD, Cardiology, clinical trial, verona pharma

Verona Pharma has announced that it will share eight posters at the American Thoracic Society International Conference (ATS) 2024, including …

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024
Manufacturing and Production Beckman Coulter Life Sciences, DNA, Pharmacy, RNA, Watchmaker Genomics, collaboration

Beckman Coulter Life Sciences and Watchmaker Genomics have announced that they have entered into a collaborative partnership with the aim …

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024
Research and Development Obesity, Veru, Wegovy, enobosarm, weight loss

Veru has announced that it has enrolled the first patients into its phase 2b clinical trial of enobosarm, an oral …

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024
Research and Development Bayer, Cardiology, cardio, cvd

Bayer and Evotec have announced that they have updated the focus of their collaboration to work on the development of …

PeptiDream and Novartis extend peptide discovery collaboration

April 30, 2024
Research and Development Novartis, PeptiDream, Pharmacy, collaboration, drug discovery, peptides

PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.

anirudh-djo3injpaoe-unsplash_3

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024
Medical Communications FDA, Haematology, Pfizer, haemophilia

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of …

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

April 29, 2024
Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …

Latest content